Table 2 Group-level characteristics of included and unavailable trials.
All trials, n = 62 | Included trials, n = 28 | Potentially eligible, unavailable trialsa, n = 34 | |
|---|---|---|---|
Drug, n (%) | |||
HCQ | 47 (76) | 24 (86) | 23 (68) |
CQ | 10 (16) | 2 (7) | 8 (22) |
Both | 5 (8) | 2 (7) | 3 (8) |
Planned sample sizea | |||
Median (IQR) | 355 (150–630) | 500 (218–1350) | 254 (120–442) |
Trial status, n (%) | |||
Active, not recruiting | 1 (2) | 0 (0) | 1 (3) |
Completed | 13 (21) | 12 (43) | 1 (3) |
Discontinued | 6 (10) | 0 (0) | 6 (18) |
Not yet recruiting | 2 (3) | 0 (0) | 2 (6) |
Recruiting | 27 (44) | 8 (29) | 19 (56) |
Terminated | 13 (21) | 8 (29) | 5 (15) |
Location, n (%) | |||
Africa | 3 (5) | 1 (4) | 2 (6) |
Asia | 23 (37) | 8 (29) | 15 (44) |
Europe | 16 (26) | 8 (29) | 8 (24) |
Internationalb | 6 (10) | 4 (14) | 2 (6) |
North America | 10 (16) | 4 (14) | 6 (18) |
South America | 4 (6) | 3 (11) | 1 (3) |
Placebo control, n (%) | 30 (47) | 11 (39) | 18 (53) |
More than two arms, n (%) | 27 (44) | 10 (37) | 17 (50) |
Patient setting, n (%) | |||
ICU | 1 (2) | 1 (4) | 0 |
Inpatient | 45 (73) | 22 (79) | 23 (68) |
Outpatient | 12 (19) | 5 (18) | 7 (21) |
Unclear | 4 (6) | 0 | 4 (12) |
Blinding, n (%) | |||
None | 32 (52) | 15 (54) | 17 (50) |
Outcome assessor | 1 (2) | 1 (4) | 0 |
Participant | 3 (5) | 1 (4) | 2 (6) |
Participant, caregiver | 25 (40) | 11 (39) | 14 (41) |
Participant, outcome assessor | 1 (2) | 0 | 1 (3) |
